Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

Background A combination of axitinib and immune checkpoint inhibitors (ICIs) demonstrated promising efficacy in the treatment of advanced renal cell carcinoma (RCC). This study aims to prospectively evaluate the safety, efficacy, and biomarkers of neoadjuvant toripalimab plus axitinib in non-metasta...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wei Zhang, Ding Zhang, Fan Xu, Wei Xue, Jin Zhang, Xiaorong Wu, Guangyu Wu, Jiwei Huang, Yueming Wang, Zaoyu Wang, Wen Kong, NG Cheoklong, Thibault Tricard, Wei Zhai, Jiyang Zhang, Shuyin Chen, Yuqing Lian, Yonghui Chen, Yiran Huang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/6/e008475.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
by: Xuan Wang, et al.
Published: (2022-02-01)

Significant response to toripalimab plus axitinib for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report and literature review
by: Xin Chen, et al.
Published: (2025-08-01)

Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma
by: Jie Cui, et al.
Published: (2025-05-01)

Pembrolizumab and axitinib induced pathological complete response in metastatic clear cell renal cell carcinoma with inferior vena cava thrombus: A case report
by: Ryan Wong, et al.
Published: (2025-01-01)

Phase Separation Investigation of Axitinib in Supersaturated Solution
by: Jie Xu, et al.
Published: (2024-11-01)

Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study
by: Zhongjie Zhao, et al.
Published: (2025-01-01)

Neoadjuvant toripalimab combined with chemotherapy in locally advanced HNSCC
by: Zhaoyang Wang, et al.
Published: (2025-05-01)

Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study
by: Chengzhi Ding, et al.
Published: (2025-04-01)

Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
by: Rebecca Wray, et al.
Published: (2025-04-01)

Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
by: Qiang Liu, et al.
Published: (2024-03-01)

The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.
by: Qian Guo, et al.
Published: (2025-01-01)

The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis
by: Qian Guo, et al.
Published: (2025-01-01)

PRSS53 is a potential novel biomarker related to prognosis and immunity in clear cell renal cell carcinoma
by: Jiajun Zhang, et al.
Published: (2025-03-01)

STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis
by: Yihui Pan, et al.
Published: (2025-02-01)

Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication
by: Francisco Socola, et al.
Published: (2012-01-01)

Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib
by: Andrew Wellen, et al.
Published: (2025-05-01)

Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities
by: Man Wang, et al.
Published: (2025-06-01)

Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America
by: Jing Yang, et al.
Published: (2025-05-01)

Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Longfeng Zhang, et al.
Published: (2025-07-01)

CT-based scoring system for diagnosing eosinophilic solid and cystic renal cell carcinoma versus clear cell renal cell carcinoma
by: Sunya Fu, et al.
Published: (2025-01-01)

Clear cell carcinoma arising from scar endometriosis: A case report and literature review
by: Chun-Jui Wei, et al.
Published: (2017-01-01)

Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
by: Edwin M. Posadas, et al.
Published: (2025-04-01)

SAP30 promotes clear cell renal cell carcinoma proliferation and inhibits apoptosis through the MT1G axis
by: Wei Guo, et al.
Published: (2025-04-01)

Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
by: Kazuhiro Watanabe, et al.
Published: (2021-01-01)

Identification of metabolic dysregulation and biomarkers for clear cell renal cell carcinoma
by: Bin Zheng, et al.
Published: (2024-12-01)

Comprehensive analysis of the leukocyte immunoglobulin-like receptor family in clear cell renal cell carcinoma
by: He Wei, et al.
Published: (2025-12-01)

Toripalimab: A new age in fighting Nasopharyngeal Carcinoma
by: Taha Ahmad Siddiqui, et al.
Published: (2025-01-01)

Genome-wide CRISPR/Cas9 screening identifies PTGR2 as a potential therapeutic target for sunitinib resistance in clear cell renal cell carcinoma
by: Wei Chang, et al.
Published: (2025-07-01)

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
by: Jia Zhong, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
by: Ming Ouyang, et al.
Published: (2025-08-01)

KCNJ2 Facilitates Clear Cell Renal Cell Carcinoma Progression and Glucose Metabolism
by: Qiyue Zhao, et al.
Published: (2025-01-01)

A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma
by: Wei Zhang, et al.
Published: (2022-01-01)

Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity
by: Yanhong Liu, et al.
Published: (2025-03-01)

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial
by: Yuqin Song, et al.
Published: (2025-05-01)

Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report
by: Wei Ning, et al.
Published: (2024-12-01)

Biomarkers associated with cell-in-cell structure in kidney renal clear cell carcinoma based on transcriptome sequencing
by: Zehua Wang, et al.
Published: (2025-04-01)

Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma
by: Haoyu Xu, et al.
Published: (2025-02-01)

NIPAL4 is an important marker for clear cell renal cell carcinoma prognosis and immunotherapy
by: Shuyan Wei, et al.
Published: (2025-03-01)

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
by: Brian Rini, et al.
Published: (2024-07-01)

Epithelial characteristics of ovarian clear cell carcinoma at single-cell resolution
by: Qinhao Guo, et al.
Published: (2025-08-01)